AI
XLRN

Atom Investors’s Acceleron Pharma XLRN Stock Holding History

Atom Investors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50,826
Closed -$2.37M – 668
2019
Q1 		$2.37M Buy
50,826
+15,277
+43% +$671K 0.2% 126
2018
Q4 		$1.55M Buy
+35,549
New +$1.78M 0.15% 160

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Atom Investors's XLRN Position: Q2 2019 in Review

Atom Investors sold out of Acceleron Pharma (XLRN) in Q2 2019, closing a stake of 50,826 shares — an estimated $2.37M sold.

Atom Investors first reported a position in XLRN in Q4 2018 and held it in 2 quarters. The position peaked at $2.37M in Q1 2019. 166 funds tracked by Wall St. Rank hold XLRN as of Q2 2019.

  • Atom Investors reported no remaining Acceleron Pharma position as of Q2 2019 after selling out during the quarter.
  • Atom Investors sold 50,826 Acceleron Pharma shares in Q2 2019, an estimated $2.37M.
  • Atom Investors first reported a position in Acceleron Pharma in Q4 2018 and held it in 2 quarters.
  • Atom Investors's Acceleron Pharma position peaked at $2.37M in Q1 2019.
  • 166 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2019.

Based on Atom Investors's 13F filing for Q2 2019, filed 14 Aug 2019.